HCID 71255363, compound → HCID 71254580, compound
Reaction equation
C([N:8](CC1C=CC=CC=1)[C:9]1([CH2:13][NH:14][C:15]2[C:24]3[C:19](=[CH:20][CH:21]=[C:22]([CH3:25])[CH:23]=3)[N:18]=[C:17]([N:26]3[CH2:32][CH2:31][C:30]([F:34])([F:33])[C:29]4[CH:35]=[CH:36][CH:37]=[CH:38][C:28]=4[CH2:27]3)[N:16]=2)[CH2:12][O:11][CH2:10]1)C1C=CC=CC=1>CO.[OH-].[OH-].[Pd+2]>[NH2:8][C:9]1([CH2:13][NH:14][C:15]2[C:24]3[C:19](=[CH:20][CH:21]=[C:22]([CH3:25])[CH:23]=3)[N:18]=[C:17]([N:26]3[CH2:32][CH2:31][C:30]([F:34])([F:33])[C:29]4[CH:35]=[CH:36][CH:37]=[CH:38][C:28]=4[CH2:27]3)[N:16]=2)[CH2:10][O:11][CH2:12]1Participants
Reactant 1
Product 1
Reagents, catalysts & solvents 2
Procedure
A solution of N-{[3-(dibenzylamino)oxetan-3-yl]methyl}-2-(5,5-difluoro-1,3,4,5-tetrahydro-2H-2-benzazepin-2-yl)-6-methylquinazolin-4-amine (190 mg, 0.314 mmol) and trifluororacetic acid (1 drop) in methanol was stirred in the presence of palladium hydroxide on carbon (50 mg) at room temperature under hydrogen atmosphere overnight. The resulting mixture was filtered, concentrated in vacuo. The residue was purified by preparative HPLC to afford 32 mg of the product as a white solid (yield was 24%). MS obsd. (ESI+) [(M+H)+] 426, 1H NMR (400 MHz, CD3OD) δ ppm 7.696 (s, 1 H), 7.654-7.636 (d, J=7.2 Hz, 1 H), 7.607-7.588 (d, J=7.6 Hz, 1 H), 7.404-7.367 (m, 2 H), 7.341-7.283 (m, 2 H), 5.011 (s, 2 H), 4.683-4.626 (m, 2 H), 4.556-4.540 (d, J=6.4 Hz, 2 H), 4.335-4.307 (t, J=5.6 Hz, 2 H), 4.084 (s, 2 H), 5.528-2.432 (m, 2 H), 2.398 (s, 3 H).
Workup
- filtrationThe resulting mixture was filtered
- concentrationconcentrated in vacuo
- customThe residue was purified by preparative HPLC
Sources & evidence
- ORD record
- ord-0d2e05d2f1614520b3186e50ccb128f9
- Source dataset
- uspto-grants-2014_10
- Patent number
- US08871756B2
Reaction notes
Loading…